Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Eisai Files Tasurgratinib for Biliary Tract Cancer in Japan
Eisai said on December 18 that it has filed a new drug application in Japan for tasurgratinib, an in-house discovered fibroblast growth factor receptor (FGFR) inhibitor previously known as E7090, for the treatment of biliary tract cancer with FGFR2 gene…
To read the full story
Related Article
BUSINESS
- Eisai Snares Japan Commercial Rights to Henlius’ PD-1 Inhibitor
February 6, 2026
- Takeda Rolls Out 31-Foot Containers for Drug Transport
February 6, 2026
- Okajima to Take Helm of Asahi Kasei Pharma in April
February 6, 2026
- PeptiDream Kicks Off PII for Radiotherapeutic Targeting Prostate Cancer
February 6, 2026
- Daiichi Sankyo Starts PI/PII Trial of ADC DS3790 in Blood Cancers
February 6, 2026
Japan’s biotech startups are coming under growing pressure as the Tokyo Stock Exchange (TSE) tightens its rules for companies listed…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…